Module 3

Immunotherapy in myeloma: focus on monoclonal antibodies

About this module

Prof Michel Delforge discusses the different types of immunotherapy in myeloma and in particular, focuses on the role of monoclonal antbodies.
This talk was filmed at the Myeloma Academy Roadshow for Haematologists in Edinburgh in May 2016.

CPD hours: 1

References

Bianchi G et al. (2015) Promising therapies in multiple myeloma. Blood 126: 300-310.

van de Donk et al. (2016) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127: 681-695.

Lonial S et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 373: 621-31.

Lokhorst H et al. (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 323: 1207-1219.

Lonial S et al. (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label randomised phase 2 trial. Lancet 387: 15551-1560.

Other

Dimopoulos M et al. (2016) Daratumumab, lenalidomide and dexamethasone for multiple myeloma. New Engl J Med. 375: 1319-1331.

Zagouri F et al. (2016) Emerging antibodies for the treatment of multiple myeloma. Expert Opin Emerg Drugs. 21: 225-237.

Take the CPD Quiz